person
as of 2026-07-01Medical Director, MD
at a glance
Roles: Study Director
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Sumitomo Pharma America, Inc.
Roles
Study Director
Trial investigator
no
Trials led
12
A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
NCT00044044Phase 2Completed
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
NCT00641745Phase 3Completed
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
NCT01143090Phase 3Completed
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
NCT00789698Phase 3Completed
A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia
NCT00088634Phase 2Completed
Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
NCT00615433Phase 3Completed
Safety and Tolerability Study of Drug to Treat Schizophrenia
NCT00044005Phase 2Completed
A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
NCT00088621Phase 2Completed
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
NCT00790192Phase 3Completed
Lurasidone Extended Use Study
NCT01485640Phase 3Completed
Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
NCT00549718Phase 3Completed
PEARL Schizophrenia Maintenance
NCT01435928Phase 3Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
STUDY_DIRECTOR
trial